IL295957A - Compounds and methods for modulating splicing - Google Patents

Compounds and methods for modulating splicing

Info

Publication number
IL295957A
IL295957A IL295957A IL29595722A IL295957A IL 295957 A IL295957 A IL 295957A IL 295957 A IL295957 A IL 295957A IL 29595722 A IL29595722 A IL 29595722A IL 295957 A IL295957 A IL 295957A
Authority
IL
Israel
Prior art keywords
compound
disease
alkyl
aryl
nucleic acid
Prior art date
Application number
IL295957A
Other languages
English (en)
Hebrew (he)
Original Assignee
Remix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remix Therapeutics Inc filed Critical Remix Therapeutics Inc
Publication of IL295957A publication Critical patent/IL295957A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Replacement Of Web Rolls (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL295957A 2020-02-28 2021-02-28 Compounds and methods for modulating splicing IL295957A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062983541P 2020-02-28 2020-02-28
US202063007333P 2020-04-08 2020-04-08
US202063040484P 2020-06-17 2020-06-17
US202063072790P 2020-08-31 2020-08-31
US202063126492P 2020-12-16 2020-12-16
PCT/US2021/020153 WO2021174164A1 (en) 2020-02-28 2021-02-28 Compounds and methods for modulating splicing

Publications (1)

Publication Number Publication Date
IL295957A true IL295957A (en) 2022-10-01

Family

ID=75143749

Family Applications (2)

Application Number Title Priority Date Filing Date
IL295957A IL295957A (en) 2020-02-28 2021-02-28 Compounds and methods for modulating splicing
IL295956A IL295956A (en) 2020-02-28 2021-02-28 Heterocyclic amides and their use for modulating splicing

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL295956A IL295956A (en) 2020-02-28 2021-02-28 Heterocyclic amides and their use for modulating splicing

Country Status (15)

Country Link
US (3) US20240190879A1 (https=)
EP (3) EP4110785A1 (https=)
JP (3) JP7736700B2 (https=)
KR (2) KR20220158238A (https=)
CN (2) CN115515679A (https=)
AU (2) AU2021228284A1 (https=)
BR (2) BR112022017188A2 (https=)
CA (2) CA3169709A1 (https=)
CL (2) CL2022002342A1 (https=)
CO (2) CO2022013832A2 (https=)
CR (2) CR20220484A (https=)
IL (2) IL295957A (https=)
MX (2) MX2022010683A (https=)
SA (1) SA522440338B1 (https=)
WO (3) WO2021174165A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020231977A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
BR112022023025A2 (pt) 2020-05-13 2023-03-28 Chdi Foundation Inc Moduladores de htt para tratar doença de huntington
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2023034812A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
IL311132A (en) 2021-08-30 2024-04-01 Remix Therapeutics Inc Splicing Modulation Compounds and Methods
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
JP2025522298A (ja) * 2022-06-15 2025-07-15 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための複素環式及びヘテロアリール化合物
WO2024086569A1 (en) 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2024086570A1 (en) 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
TW202440080A (zh) * 2023-03-01 2024-10-16 美商雷密克斯醫療公司 用於調節剪接之化合物及方法
WO2024182788A1 (en) * 2023-03-01 2024-09-06 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202535379A (zh) * 2024-01-26 2025-09-16 大陸商成都微芯藥業有限公司 Ｕｓｐ１抑制劑及其製備方法和用途
CN118166099B (zh) * 2024-02-05 2024-10-22 北京大学深圳医院 检测hsa_circ_0014088的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4809656B2 (ja) * 2005-09-29 2011-11-09 富士フイルム株式会社 ナフタロシアニン色素およびその製造方法
US20070254894A1 (en) * 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
EA201501088A1 (ru) * 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
US20100029657A1 (en) * 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
GB0807910D0 (en) * 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
ES2554513T3 (es) * 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
US20110288089A1 (en) * 2009-01-22 2011-11-24 Syngenta Crop Protection Llc Insecticidal compounds
EP2435421A1 (en) * 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201202230A (en) * 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
AU2011273931B2 (en) * 2010-06-28 2015-04-23 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
JP2012028440A (ja) * 2010-07-21 2012-02-09 Hitachi Kokusai Electric Inc 基板処理装置及び半導体装置の製造方法
DK2812004T3 (en) 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
MX336431B (es) * 2012-05-09 2016-01-18 Zoetis Services Llc Derivados de azetidina como agentes antiparasitarios.
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
KR20140125061A (ko) * 2013-04-18 2014-10-28 (주)경인양행 유기발광 화합물 및 이를 포함하는 유기전계발광소자
WO2014209841A2 (en) * 2013-06-25 2014-12-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
BR112016026951B1 (pt) * 2014-06-25 2022-09-20 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pirazin-1-il-benzamida, seu uso, e composições farmacêuticas
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
JP2017528498A (ja) * 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
CN104341403B (zh) * 2014-10-10 2016-06-22 山东盛华电子新材料有限公司 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法
NL2013636B1 (en) * 2014-10-15 2016-10-04 Kraton Polymers Us Llc An accelerator system, a composition comprisng a synthetic isoprene polymer and the accelerator system, and dipped goods made from the composition.
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
US10259816B2 (en) * 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
WO2017147328A1 (en) * 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
EA201991309A1 (ru) 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
EP3573954A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11407753B2 (en) * 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
WO2019028440A1 (en) * 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
KR20200057071A (ko) 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물
EP3697786B1 (en) * 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
TW201942115A (zh) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
CN112272666A (zh) 2018-04-10 2021-01-26 斯基霍克疗法公司 用于治疗癌症的化合物
PL3814357T3 (pl) * 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
BR112020026637A2 (pt) * 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
TWI834690B (zh) * 2018-07-18 2024-03-11 美商富曼西公司 用於防治無脊椎動物害蟲之異噁唑啉化合物
CN109180690A (zh) * 2018-10-15 2019-01-11 烟台显华化工科技有限公司 一类用作蓝色荧光材料的氮杂芳香化合物及其应用
WO2020123395A1 (en) * 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2020132459A1 (en) * 2018-12-20 2020-06-25 The Regents Of The University Of Michigan Quinolinyl-pyrazine-carboxamide compounds and uses thereof
AU2020260629A1 (en) * 2019-04-22 2021-12-09 Betta Pharmaceuticals Co., Ltd Quinazoline compound and pharmaceutical application thereof
WO2021007378A1 (en) * 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease

Also Published As

Publication number Publication date
CN115485025A (zh) 2022-12-16
WO2021174164A1 (en) 2021-09-02
CA3169709A1 (en) 2021-09-02
IL295956A (en) 2022-10-01
BR112022017210A2 (pt) 2022-10-25
JP7736700B2 (ja) 2025-09-09
MX2022010684A (es) 2023-01-19
JP2023515621A (ja) 2023-04-13
EP4110464A1 (en) 2023-01-04
WO2021174165A1 (en) 2021-09-02
US20230365566A1 (en) 2023-11-16
MX2022010683A (es) 2023-01-19
KR20220159386A (ko) 2022-12-02
CO2022013832A2 (es) 2022-10-31
BR112022017188A2 (pt) 2022-11-08
CN115515679A (zh) 2022-12-23
CR20210483A (es) 2022-11-25
US20240226098A1 (en) 2024-07-11
AU2021228284A1 (en) 2022-09-29
CO2022013827A2 (es) 2022-10-31
US20240190879A1 (en) 2024-06-13
AU2021228767A1 (en) 2022-09-29
JP2023515620A (ja) 2023-04-13
JP2025172876A (ja) 2025-11-26
JP7847852B2 (ja) 2026-04-20
EP4110459A1 (en) 2023-01-04
SA522440338B1 (ar) 2025-01-29
CL2022002341A1 (es) 2023-03-10
KR20220158238A (ko) 2022-11-30
EP4110785A1 (en) 2023-01-04
CL2022002342A1 (es) 2023-03-17
CA3169691A1 (en) 2021-09-02
CR20220484A (es) 2022-12-15
WO2021174163A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
IL295957A (en) Compounds and methods for modulating splicing
IL295953A (en) Pyridazine derivatives regulate nucleic acid splicing
IL295955A (en) Compounds and methods for modulating splicing
JP2023515617A5 (https=)
CA3093405C (en) POLYBROMO-1 SMALL MOLECULE DEGRADING AGENTS (PBRM1)
CN108349964B (zh) N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
JP2023515620A5 (https=)
JP2023520924A5 (https=)
JP2013508373A5 (https=)
WO2016097869A4 (en) Fused ring heteroaryl compounds and their use as trk inhibitors
JP2023515621A5 (https=)
JP2014506599A5 (https=)
US20040010037A1 (en) Cyanophenyl derivative
RU2004126671A (ru) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
AU2018200461B2 (en) Process methods for phosphatidylinositol 3-kinase inhibitors
JP2014503574A5 (https=)
JP2023520925A5 (https=)
JP2013504593A5 (https=)
JP2009534358A5 (https=)
JP2015531773A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
JP2010525057A5 (https=)
JP2011500758A5 (https=)
JP2019527724A5 (https=)
JP2018529690A5 (https=)
JP2016513696A5 (https=)